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these guidelines, national opioid use in this population has
declined significantly.(8,9)

Background

Opioids are commonly used in the pediatric pain management
paradigm. In an earlier cross-sectional observational study,
64% of clinicians were reported to have prescribed an opioid
to manage acute pain in pediatric patients.(10) Managing opioid
usage in children needs to be personally tailored and monitored
closely due to the developmental changes in young children
and adolescents. Their unique developmental characteristics
result in the distinct pharmacodynamic and pharmacokinetic
features which differ from those seen in adults.(11) Although
guidelines exist for opioid prescription in pediatrics(12-14), the
resources and training provided to healthcare professionals
are limited. This makes pain management in the pediatric
population more challenging, especially in outpatient settings,
and often leaves prescribers to rely on their clinical judgment
and experience when prescribing opioids.(2,15)

Receipt of opioid prescriptions in pediatric and young adult
patients may be a risk factor for future opioid misuse. Data
from prescription drug monitoring programs provide insight
on outpatient opioid use. In our study, we analyzed the opioid
dispensing rates for pediatrics and young adults in California.

Methods

A secondary analysis was performed from 2015-2019 using
Controlled Utilization Review and Evaluation System data. This
database provides dispensing data of controlled substances in
California. Patients younger than 25 years who were prescribed
opiates were analyzed by county. We further divided them into
two groups (children: ≤14 years; adolescents and young adult:
15-24 years). Descriptive statistics and heat maps were used to
illustrate the trends in opioid usage among different age groups.

Results

The overall percentages for the number of opioids being
dispensed to patients aged <25 years have decreased over
the past four years. In 2015, 6 out of 58 counties in California
were considered “high-rate” with >2.9% of opioids dispensed
to patients younger than 25 years old; in 2019, this number
reduced to zero. Patients 25 and older received a higher
proportion of opioids compared to younger populations; in
2019, 35.91% of opioids were dispensed to patients 45-64,
and 8.92% to patients younger than 25.

Conclusion

Pediatric opioid prescriptions have declined over the recent
years. However, a high degree of variability of prescription
rates between demographic counties was noted. More studies
are warranted in order to understand this discrepancy in
opioid prescribing among pediatric and young adult patients.

Introduction

The opioid epidemic has been widely viewed as a serious
public health problem that has been focused primarily on
adults in the US. However, a similar pattern of increased
prescribing rates of opioids in adolescents and young adults
have also been noted.(1,2) This pattern of opioid use in this
patient population has contributed to increased reports of
accidental poisoning, misuse and abuse, overdose-related
hospitalizations, and death.(3-5) From 1999-2016, the pediatric
mortality rate increased by 268% in children and adolescents
due to opioids.(6) In an effort to enhance consistency in the
prescribing of opioids, the CDC published its first guidelines
regarding the use of opioids in 2016.(7) Since the release of

There has been a significant pullback from opioid prescribing
in both adults and pediatric patients. From 2012 until 2018,
the overall opioid prescribing rates fell from 81.3 to 51.5
prescriptions per 100 persons.(8) With the heightened attention
being placed on the use of opioids overall and growing
concerns over the use of opioids within pediatric and young
adult populations, there is a growing number of research studies
being published. However, few studies to-date have focused on
state-specific or county-level analysis. Previous research that
analyzed variations in regional opioid use across the United
States did show higher rates of opioid prescribing for pediatric
and young adult patients in the western region of the United
States, which includes the state of California, as compared
to opioid prescribing rates in other areas of the country.(9) To
better understand the use of opioids among pediatric and
young adult patients in California, we conducted an analysis
of publicly available data from the state’s controlled substance
reporting system. The goal of the study was to examine countylevel trends in opioid prescribing in pediatrics and young adults
in California from 2015 to 2019. The California Controlled
Substance Utilization Review and Evaluation System (CURES)
data, which is collected by the California Department of Justice
(DOJ), was used for the analysis of the study.

Objective

The primary outcome of the study is to assess the changes
in county-level opioid dispensing rates to pediatric and young
adult patients in California from 2015-2019. A secondary
outcome is identifying whether the presence of a pediatric
hospital within the county impacts the likelihood the county
is deemed a “high-rate” county, defined as having a high
magnitude of opioids dispensed to pediatrics and young adults.
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Methods
CURES Database

The Controlled Substance Utilization Review and Evaluation
System (CURES) is a prescription drug monitoring program
that longitudinally tracks all Schedule II-IV controlled
substance prescriptions dispensed in the state through
California’s Department of Justice (DOJ). The DOJ provides
aggregated reports to the general public based on the data
collected through the CURES and makes them available
online.(16) All data analysis conducted as part of this study were
conducted using the aggregated datasets available from the
publicly available online reports published from 2015-2019.(16)

Study Population

The CURES data used to complete the analysis of the study
includes all information reported for opioid prescriptions
dispensed in California. This data included reports of the
number of patients dispensed opioids, broken up by the year,
county, and preset age groupings. Stratification of age was
maintained from the reported age groups in the DOJ’s publicly
reported CURES statistics. All 58 counties in California were
included in the study.

Study Outcome

The primary outcome of the study was the changes in countylevel opioid dispensing rates to pediatric and young adult
patients in California from 2015-2019. Our secondary outcome
was identifying whether the presence of a local pediatric
hospital is associated with a county’s likelihood of being a
“high-rate” county, defined as having a high magnitude of
opioid prescriptions to pediatrics and young adults.

Statistical Analysis

Descriptive statistics and heat maps were used to illustrate
trends in opioid prescribing among different age groups and
demographic regions and counties over the years studied. The
total number of opioid prescriptions was collected from the
datasets and analyzed in comparison to other demographic
regions and counties in California. Opioid prescription trends
were evaluated through three methods.

24

Proportion of opioids dispensed to pediatrics and young
adults: The next analysis examined the proportion of opioids
prescribed to the pediatric and young adult population,
comparing it to the total number of opioids prescribed in each
county. Specifically, patients aged 15-24 years old in their
respective counties were examined, broken down by year.
Using the same method, the distribution of opioid prescriptions
across each specific age group (≤14, 15-24, 25-44, 45-64, ≥65)
in their respective county was visualized. Proportions of opioid
prescriptions for each specific age group were calculated and
demonstrated in the heatmap format using a color scale,
where the red color represents the highest proportions seen.
Prevalence of a pediatric hospital on opioid dispensing rate:
The last point examined opioids dispensed to patients ≤14
years old within the total population of the county. As in the
first analysis, “high-rate” counties were defined by rates
which were one standard deviation above the average rate
reported in 2015, which was calculated to be 2.18%. These
counties were highlighted in red and children’s hospital
locations were identified and marked on the map.

Results
Based on census data, there were 37 million residents in
California within our study time period, 2015-2019. During the
individual years reported, the year of 2015 had the highest
number of individual patients with an opioid prescription
dispensed, with 7.12 million total patients receiving an opioid.
In 2016, the number of patients with opioid prescriptions
significantly decreased, with 4.81 million patients receiving an
opioid (Table 1). Following the substantial reduction in overall
number of patients being dispensed opioids from 2015 to
2016, the number of patients remained relatively stable from
2016 to 2019. In the final year of reporting, 5.01 million patients
received an opioid in 2019. A similar trend also persisted when
examining other metrics such as total morphine equivalent
dose (MME) prescribed, CII-IV pill count, and total CII-IV
prescription count per year. Notably, a higher quantity of CII
pills and prescriptions were dispensed to the pediatric and
young adult population each year compared to the amount
of CIII-IV substances given to the same population (Table 1).
When evaluating patients younger than 25 years of age,
similar patterns of dispensing were present. Similar to the
overall statewide population, patients 24 years old or younger
reported the largest number of patients dispensed an opioid
in 2015 (780,630 patients), followed by a significant drop
in patients dispensed an opioid in 2016 (473,764 patients),
followed by a significant increase in 2017 (643,709 patients),
and eventually noting a consistent decrease from 2018
(537,197 patients) to 2019 (454,002 patients) (Table 1).
The number of “high-rate” counties for those aged <25 years
old significantly decreased from six in 2015 to zero thereafter.
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California state law requires dispensing pharmacies, clinics,
or other dispensers of Schedule II-IV controlled substances
to provide specified dispensing information to the DOJ on a
weekly basis. The patient’s identifiable information, such as
name, date of birth, gender, and address, are also recorded,
in addition to the prescriber and pharmacy identities with DEA
registration numbers. The publicly available data provided by
the DOJ used to conduct this research study are a series of
limited datasets which have been deidentified and reported
as aggregates based on various patient and provider factors.
For example, metrics such as morphine milligram equivalents
(MME) and pill counts were automatically calculated by CURES
and prepared as composite data from the CA DOJ. This study
is exempt from Institutional Review Board (IRB) approval, given
the nature of the data analyzed. The public CURES database
includes the number of patients receiving opioid prescriptions
in a patients’ locale based upon the county, gender, age group
(≤14 years, 15-24 years, 25-44 years, 45-64 years, and ≥65
years), and year, from 2015 to 2019. To analyze how opioid
dispensing rates are affected by the presence of children’s
hospitals, these hospitals were identified using a directory
available from the Children’s Hospital Association.(17)

Overall rate of opioids dispensed to pediatric and young
adult patients: First, the percentage of pediatric and young
adults (<25 years old) dispensed opioids in each county was
examined. “High-rate” counties were defined as counties
that had a calculated percentage of opioid dispensing greater
than 2.9% of the population, which is one standard deviation
above the average rate reported in 2015, and is also the
rate that marked the 80th percentile of counties in 2015.
The trends were determined by comparing the heatmaps
generated by different years.

Table 1. Characteristics of the CURES database collected by the California Department of Justice from 2015-2019.
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"-" means data not available based on the publicly-available databases posted online.
* the total population is based on US Census Data that was aggregated by the California Department of Justice and is representative
of the population from 2015-2019(16)
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Comparing opioid dispensing rates on a county-level from
2015-2019, counties overall reported reduced numbers of
opioid prescriptions dispensed to patients younger than 25
years. However, the rate of dispensing in central California
counties persistently remained higher than that of other regions.
In addition, at an overall state-level of reporting, as well as,
within individual counties, there was an increase in the number
of patients aged less than 25 years old being dispensed an
opioid prescription from 2016 to 2017, followed by a steady
decline afterwards. As shown in Table 1, the overall number of
patients being dispensed an opioid has declined approximately
10% and 11% per year on average among pediatric (≤14 years)
and young adult (15-24 years old) patients, respectively.

Among all the opioid prescriptions, the amount of opioids
dispensed to individuals aged 25 years and older was
consistently higher than those under the age of 25 years old.;
similar patterns were observed in every year examined (Figure
3). The average percentage of opioids being dispensed to
individuals ≤14 years old in 2015 was 1.63%, which is similar
to the 1.25% recorded in 2019. The average percentage of
total opioids dispensed to adolescents and young adults (1524 years old) in 2015 was 9.11%, with the actual percentage
dropping to 7.29% in 2019 (Figure 2). Compared to other
age groups, individuals ≤14 years old received the lowest
percentage of opioid medications over the years (Figure 3). On
average, approximately 27.2%, 37.5% and 24.6% of opioids
prescriptions were dispensed to patients aged at 25-44, 4564, and 65+ years old respectively in 2015, and in 2019, those
averages shifted to 23.46%, 35.91%, and 32.08% respectively.
For individuals aged 14 years old and younger, counties were
deemed “high-rate” if the rate of opioids prescriptions given
to these patients exceeded 2.18%, or one standard deviation
above the average rate of opioids dispensed to patients in
this age range (Figure 4). Rates were calculated as opioids
dispensed per total population, and “high-rate” counties were
marked in red. In 2015, there were seven identified “high-rate”
counties for patients ≤14 years old. The following year, the total
number of high-rate counties dropped to 3, and then increased
back to 4 in 2017. By 2019 the number of “high-rate” counties
had dropped to zero. Overall, most of the “high-rate” counties
that had a prescription rates above 2.18% in individuals aged
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When evaluating counties being deemed to be “high-rate”
counties in relationship to opioid dispensing to individuals
aged 14 years old or younger, none of the “high-rate” counties
had a registered children’s hospital located within the county.
Due to the absence of registered children’s hospitals in any of
the “high-rate” counties, there was no possibility of running a
statistical test to examine differences in opioid-use associated
with the presence of a hospital from which to draw a conclusion.
When evaluating the location of children’s hospitals and the
relationship to opioid dispensing, there did not appear to be
an association with higher rates of opioid dispensing among
those aged 14 years old and less, as none of the “high-rate”
counties contains a registered children’s hospital.

Discussion
In our study, we consistently observed a decline in opioid
prescriptions from 2015 to 2016 among all patient populations
recorded in California. The timing of this downtrend is
consistent with trends reported nationally and coincides
with the release of the updated CDC guidelines for opioid
prescribing that encourage a general reduction in opioid use
across most clinical situations.(7,9,18) To our knowledge, this
is the first study examining county-level opioid dispensing
in California within the time period of this study. Although
studies examining national trends generally agree that the use
of opioids in pediatric patients has overall decreased in recent
years, there is uncertainty with how specific regions contribute
to the trend – one study reported the western states with
having the lowest prescribing rates(19), while another found
the West to have the highest.(9) A notable point of observation
is that the CDC guidelines exclude patients younger than
18 years old; yet, our results suggest that patients younger
than 18 have also experienced a decline in opioid prescribing
after the publication of the updated CDC guidelines. It is
uncertain to what degree that the guideline updates have
affected opioid use in the pediatric, adolescent, and young
adult population. However, it is likely that practitioners have
interpreted these guidelines to suggest that opioids should be
restricted for use in these populations in situations where no
other pain management strategy is likely to achieve necessary
pain reduction. Although it is not possible for us to validate
any causes for the decline of opioid prescriptions based
on the current CURES data, our study suggests that there
may be a potential impact from the CDC guideline upon the
decrease in opioid prescribing among pediatric patients given
the congruence of the timeline. In addition, the results of our
study suggest that following an initial sharp decline in the
number of patients being prescribed an opioid from 2015 –
2016, there was a significant rebound effect seen in 2017. This
may be the result of practitioners reducing opioid prescribing
too rapidly. The steady decline observed from 2017 through
2019 suggests that practitioners once again made efforts to
reduce opioid prescribing after the 2017 rebound.
This decline of opioid prescriptions among pediatric and young
adults also aligned with the mandate for all California licensed
prescribers to register for access to CURES by 2016, and for
mandatory CURES consultations to start in 2018.(20) From
January 2016 to January 2017, there was a 176% increase in
registered CURES prescribers in California; within pharmacy,
there was a 64% increase of pharmacists.(21) This and other
efforts being made within the state of California to reduce overall
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When specifically evaluating the proportion of patients aged
15-24 years old accounting for opioid prescriptions dispensed,
this proportion has decreased each year since 2015, with 1524 years old accounting 9.38% of patients dispensed an opioid
in 2015 dropping to 7.82% in 2019 (Figure 2). For this age
group, higher proportions of dispensed opioids were observed
in central and southern California than in other regions, with
relatively fewer changes in the later years. Alpine County
reported that 15.23% of individuals aged 15-24 were dispensed
an opioid in 2015, the highest percentage of the state that year.
The county with the lowest percentage was Trinity County, with
a rate of 3.56% in 2019. The largest year over year proportion
drop of any county was observed in Alpine Country from 2015
– 2016, with a proportion of 15.23% in 2015 and 5.79% in
2016 (an absolute proportion drop of 9.44%). However, Alpine
also noted a significant surge in this proportion from 20162017, increasing by an absolute proportion of 8.3%. Of note,
given the high number of individuals aged 15-24 years having
an opioid dispensed among residents, Alpine County also
accounted for the highest proportion of opioids within this age
group in every year of the analysis, with the exception of 2016.

14 years old or younger were located in Central California.

Figure 1. Opioid dispensing rates to patients younger than 25 years old (2015-2019).(16)*
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*Rates were calculated as total opioids dispensed per total population of the respective county.

Figure 2. Proportion of opioids dispensed to 15-24 year old patients.(16)*

*Proportions calculated as opioids dispensed to 15-24 year olds among total opioids dispensed per respective counties in California
from 2015 to 2019.
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Figure 3. Comparison of opioids prescriptions among different age groups in 2015 and 2019 from data collected by DOJ.(16)*
A) ≤14 years old; B) ≥ 65 years old.

A
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*Proportions calculated as opioids dispensed to the age group of interest per total opioids dispensed within the county.
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Figure 4. Children hospitals near the “high-rate” counties in CA from year 2015-2019.*

opioid prescribing may have contributed to the drop in opioid
dispensing rates following the 2017 rebound. Similar reductions
in opioid use were also observed in other studies which examined
state opioid prescribing rates after the implementation of a
prescription drug monitoring program (PDMPs).(22,23) Studies have
also demonstrated a reduction in the prescribing of schedule II
opioids after mandating registration to PDMPs.(24) While the initial
intent of a PDMP is to reduce the number of prescriptions given
to high-risk drug abusers by identifying patients who regularly
fill controlled substances, there may have been a secondary
effect where prescribers and dispensers adjusted their overall
prescribing and dispensing practices due to the heightened
awareness of PDMPs.
In California, the total number of dispensed schedule II
substances to pediatric and young adults also declined over
the 4-year period, with the biggest drop occurring in 2016.
The specific drug breakdown is not available with the given
dataset, which restricts the ability to distinguish which of those
schedule II substances dispensed were opioids. However, it
was noted that a higher amount of schedule II substances
was dispensed to the pediatric and young adult population,
compared to the schedule III or IV substances. This may
warrant further examination, as pediatric exposure to schedule
II opioids has been shown to result in a higher likelihood of
future alcohol use disorder, cannabis use disorder, or any other
drug use disorder, compared to opioids belonging to "lower"
scheduled controlled substance classes.(25)
Our study also revealed that there was a disproportionate
decrease in opioids among the different age ranges. Patients
older than 65 had the smallest degree of reduction in opioids
dispensed, whereas pediatric and young adult patients had the
some of the largest reduction rates. Thus, the fraction of total
opioids dispensed to patients older than 65 increased, while
the percentage dispensed to younger patients decreased.
This trend suggests that there has been exceptional efforts in
diminishing opioid use in age groups deemed at risk of misuse,
namely, younger populations such as pediatrics and young
adults. Meanwhile, older populations such as those above 65
years old, may have persistently higher rates due to population
characteristics such as more cases of palliative care and
chronic pain. Opioid prescriptions for younger populations

tend to treat acute issues such as surgical procedures and
sport injuries – inherently, these medical issues tend to capture
opioid naïve patients who are less likely to require a prolonged
use of opioid compared to chronic pain patients. Therefore, the
discrepancy observed in opioid prescribing among different
age groups may be driven by the differences in their medical
conditions that are typically experienced in each age group.
Although the fraction of patients who received opioids at ages
15-24 years old was relatively small compared to older age
groups, providers should continue to be diligent with opioid
use in this population due to concerns for misuse and abuse.
The probability of prescription opioid abuse declines with
increasing age at the first opioid exposure, with the peak risk
being observed in patients using opioids for the first time as
adolescents or young adults aged 18-24 years old.(26) This
age group itself has been shown to be a risk factor for drug
abuse(27,28), which only further compounds the problem.(29,30)
Additionally, a previous study examining the CURES database
found that younger patients and female patients were
associated with using multiple prescribers and pharmacies
for opioid prescriptions.(31) However, the data from this study
is limited as it examines opioid prescriptions in 2006, which
is significantly earlier than the data used in our study. Another
study examining CURES opioid prescriptions from 1999 until
2007 revealed that the highest increase of opioid use was
among 18-44 year old females, whereas males aged 65 and
older had the lowest rate of increase.(32) Juxtaposed with our
study, which takes place during an overall effort to curb the
opioid crisis, we observed an overall decline with the most
change appearing to occur among patients younger than 25.
To our knowledge, few studies exist that examine county level
factors in California that affect opioid prescribing. Since a
large percentage of pediatric opioid prescribing comes from
hospitals at discharge(33,34), we attempted to determine if the
presence of a pediatric hospital would affect opioid prescribing
rates. Our results found that none of the “high-rate” counties
had a pediatric hospital, which may indicate that the presence
of a pediatric hospital equipped with pediatric-specially
trained providers may improve opioid prescribing practices.
Additional studies are needed, as others have suggested that
opioid prescribing practices between general and pediatric
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*Children hospital or specialty clinics were based on the information from the Children’s Hospital Association.(17) “High-rate” counties
were defined as counties that were one standard deviation above the average opioid dispensing rate in 2015.

Another important consideration is the proportion of opioid
prescriptions given per patient, as some opioid prescription
rates may be driven by individuals receiving a substantial
number of opioid prescriptions and those demonstrating
drug-seeking behaviors, such as doctor-shopping. Our results
show that less than 1% of patients are non-unique patients,
but it is unclear how this number is distributed among those
aged less than 25 years old. Additionally, non-unique patients
who receive an opioid are not necessarily misusing opioids
and may simply be managing more long-term pain disorders.
Other studies examining CURES data has suggested that
past rates of doctor shopping ranged from 1.25% to 5.31%,
with the highest number being female patients older than 65;
pediatric and young adult populations were not considered a
high risk group.(32) Factors that affect multiple prescriber and
pharmacy utilization among opioid users is understudied,
but it is suspected that these factors may be similar to those
that predict illicit drug use, such as psychological factors,
socioeconomic status, and neighborhood disadvantage.(38-40)
Seeking multiple prescribers may also be driven by clinically
legitimate reasons, such as having multiple comorbidities
that are treated by separate physicians, or suffering from
undertreated pain due to the restricted opioid prescribing after
the publication of the CDC guidelines.(41,42) Although our data
does not reveal age-specific information related to individuals
being dispensed multiple opioid prescriptions, it suggests
that there remains a very low number of patients that are nonunique opioid recipients in California from 2015 to 2019.
Ultimately, the tightening of opioid prescribing and dispensing
is intended to improve public health outcomes and reduce
overdose morbidity and mortality. According to the CDC,
there was an overall reduction in deaths due to opioid
prescriptions in California from 2014-2018.(43) Yet, deaths due
to illicit and synthetic opioids have increased in the state,
which have been driving up the overall opioid mortality rates.
This is also mirrored on a national scale(3,4), which enforces
the complexity of the opioid climate. Simply reducing opioid
prescriptions does not improve the opioid mortality rate and
further investigation is needed to identify effective researchdriven policies surrounding opioid use.(44,45)

Limitations

Given the retrospective, cross-sectional nature of the
study, we are limited to reporting opioid prescribing rates
and are restricted from conducting further predictive or
causal analyses. While CURES data captures all controlled
prescriptions that are dispensed through a pharmacy, it

30

does not include federally regulated pharmacies, such as
those under the jurisdiction of the Department of Defense
and Indian Health Services. The application of our findings is
also limited, as it lacks comparison to other states’ pediatric
prescribing rates during the same studied time period. Further,
not every pediatric-specific hospital may have been captured
in this study, as it is not mandatory to join the Children’s
Hospital Association. Another limitation of this study is its
lack of analyzable variables that have been shown to affect
opioid prescribing rates, such as sex/gender. This analysis
was limited to the available information that was published
on the CA DOJ website, which provided aggregate data sets
with restricted manipulation. Therefore, we were unable to
perform additional subgroup analyses and account for other
demographic factors such as different age groupings, sex,
race/ethnicity, and medication information (e.g. opioid name,
quantity, and prescriber information).

Conclusion
There has been an overall downtrend of pediatric and young
adult patients on opioid prescriptions in California. Safer
practices in this population should not be limited to reducing
opioid prescriptions, as evidenced by the continued prevalence
of opioid deaths despite the downtrend of prescribed opioids.
Older adolescents and young adults are at risk of opioid
misuse and abuse – identifying the environmental and intrinsic
mechanisms that lead to this risk is essential, and targeting
communities and regions with the higher risk may mitigate
the issue substantially. Efforts aimed at public health policies
should be specific and target at-risk populations, rather than
be generalized, as this may prove ineffective.
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hospitals are similar to one another.(35) Other sources of opioid
prescriptions may be driving county-level factors, as there is a
positive correlation between the number of available physicians
within a patient’s residential county and number of prescribers
and pharmacies that a patient uses per year.(36) In respect to
national trends, one study examining congressional districts in
2016 observed that Northern California, Eastern Arizona, and
Nevada had relatively high opioid prescribing rates, second
only to areas along the Appalachian and throughout the South.
(37)
The same study also found that 3 of the 10 lowest rates were
from regions in California. In addition, county-based factors
such as median household income, average educational
attainment, race/ethnicity, and physician availability may also
significantly impact patient’s choice of multiple prescribers and
pharmacies.(31) How this information translates to opioid use in
pediatrics is unclear, and warrants further investigation.
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